PG
IOVA icon

PEAK6 Group’s Iovance Biotherapeutics IOVA Stock Holding History

PEAK6 Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,856
Closed -$147K – 4877
2016
Q3 		$147K Buy
17,856
+4,388
+33% +$37.1K ﹤0.01% 3347
2016
Q2 		$109K Buy
+13,468
New +$84.6K ﹤0.01% 3529

Other funds holding IOVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PEAK6 Group's IOVA Position: Q4 2016 in Review

PEAK6 Group sold out of Iovance Biotherapeutics (IOVA) in Q4 2016, closing a stake of 17,856 shares — an estimated $147K sold.

PEAK6 Group first reported a position in IOVA in Q2 2016 and held it in 2 quarters. The position peaked at $147K in Q3 2016. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

  • PEAK6 Group reported no remaining Iovance Biotherapeutics position as of Q4 2016 after selling out during the quarter.
  • PEAK6 Group sold 17,856 Iovance Biotherapeutics shares in Q4 2016, an estimated $147K.
  • PEAK6 Group first reported a position in Iovance Biotherapeutics in Q2 2016 and held it in 2 quarters.
  • PEAK6 Group's Iovance Biotherapeutics position peaked at $147K in Q3 2016.
  • 87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on PEAK6 Group's 13F filing for Q4 2016, filed 13 Feb 2017.